ACTUAL ASPECTS OF MOLECULAR-BIOLOGY CLASSIFICATION OF BREAST CANCER

DOI: https://doi.org/None

D.V. Bulanov European Medical Center, Oktyabrskaya Str., 33a, Moscow, Russian Federation, 127018

There is represented immunohistochemical and molecular biological characteristic of some histological types of breast cancer. The assessment of molecular biomarkers in breast cancer has two practical results: identification of risk groups, requiring additional treatment or more careful observation among patients with early-stage, and evaluation of the sensitivity to certain types of therapy individualization of treatment regimens in patients with extensive process. Invasive breast carcinoma represents a heterogeneous group of tumors with a wide variation in relation to clinical manifestations, prognosis and morphological spectrum. Gene expression profiling with the use of molecular biological methods in ductal breast carcinomas of unspecified type confirmed that major prognostically significant factors in the clinical course of breast carcinoma are: the presence of the hormone-receptor-related genes and gene family of epidermal growth factor (HER2related genes), as well as genes that determine the proliferative activity of tumor cells (proliferation-related genes). Additionally to defects genome detectable in tumors revealed immunophenotypic and molecular biological heterogeneity were shown to determine the clinical course and prognosis of survival.
Keywords: 
breast cancer, gene, HER2, immunohistochemical characteristics, BRCA

Список литературы: 
  1. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378 (9805): 1812–23.
  2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490 (7418): 61–70.
  3. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010; 220 (2): 263–80.
  4. Cheang M.C., Chia S.K., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 2009; 101 (10): 736–50.
  5. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363 (20): 1938–48.
  6. Badve S., Dabbs D.J., Schnitt S.J. et al. Basal-like and triple negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011; 24 (2): 157–67.
  7. Joosse S.A., Brandwijk K.I., Mulder L. et al. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011; 50 (2): 71–81.
  8. Collins L.C., Martyniak A., Kandel M.J. et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple negative breast cancers. Am. J. Surg. Pathol. 2009; 33 (7): 1093–7.
  9. Molyneux G., Geyer F.C., Magnay F.A. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem. Cell. 2010; 7 (3): 403–17.